NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
09/10/2024
Back to search
Official data from USPTO
COMPUGEN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
COMPUGEN
ST13
US500000087284523Class
5, 42, 45
Filing
87284523
Registration
5640243
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
09/10/2024
Trademark type
Word
Nice classes
5, 42, 45
Filing date
12/29/2016
Registration date
01/01/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/10/2024
Last transaction
09/10/2024
Responsible office
United States Patent and Trademark Office
Status code
705
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
First use anywhere
09/08/2004
First use in commerce
09/08/2004
Drawing code
4
Owner type
03
Owner location
Holon, IL
Examiner
REEVES, APRIL
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Compugen Ltd.
Representatives
Kevin D. McCarthy ROACH BROWN MCCARTHY & GRUBER, P.C.
Technical classification
Nice Classes
Class 5Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
(Based on 44(e)) biological preparations featuring antibodies for the treatment of cancerinflammatory diseasesautoimmune diseasesneurological diseasescardiovascular diseasesmetabolic diseasesgastrointestinal diseases; anti-cancer preparations; biological preparations for the treatment of cancer inflammatory diseasesautoimmune diseasesneurological diseasescardiovascular diseasesmetabolic diseasesgastrointestinal diseases; biopharmaceuticals for the treatment of cancer; diagnostic reagents for medical purposes; pharmaceutical preparations for the treatment of autoimmune diseases
Class 42
(Based on Use in Commerce) (Based on 44(e)) Drug discovery services; scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of genetics; research and development in the field of diagnostic preparations; research in the field of pharmacogenetics; conducting clinical trials for pharmaceuticals; pharmaceutical research and development; research and development in the field of pharmaceuticals for the pharmaceutical industry; conducting early evaluations in the field of new pharmaceuticals; research services in the field of proteinsantibodiesmicroorganisms and cells; research and development services in the field of antibody technology; structural and functional analysis of genomes; DNA screening for scientific research purposes; biochemical research and analysis; laboratory research in the field of pharmaceuticals; research and development services in the field of immunology; medical research in the nature of computerized genetic analysis of DNA
Class 45
(Based on 44(e)) Licensing of intellectual property rights
Publications
History of USPTO decisions and trademark events.
30 publications found
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
09/10/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/10/2024
E815
TEAS SECTION 8 & 15 RECEIVED
02/27/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
01/01/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
01/01/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/16/2018
PUBO
PUBLISHED FOR OPPOSITION
10/16/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/26/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/06/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/17/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/17/2018
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
08/15/2018
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
05/06/2018
GNSI
INQUIRY TO SUSPENSION E-MAILED
05/06/2018
CNSI
SUSPENSION INQUIRY WRITTEN
05/06/2018
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
04/26/2018
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
10/14/2017
GNSL
LETTER OF SUSPENSION E-MAILED
10/14/2017
CNSL
SUSPENSION LETTER WRITTEN
10/14/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/19/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/19/2017
ALIE
ASSIGNED TO LIE
09/15/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/07/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/02/2017
GNRT
NON-FINAL ACTION E-MAILED
04/02/2017
CNRT
NON-FINAL ACTION WRITTEN
04/02/2017
DOCK
ASSIGNED TO EXAMINER
03/26/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/10/2017
NWAP
NEW APPLICATION ENTERED
01/02/2017
Continuous trademark protection
Get notified about every new filing that threatens COMPUGEN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.